Free Trial
NASDAQ:CRTX

Cortexyme (CRTX) Stock Price, News & Analysis

Cortexyme logo
$1.32 +0.05 (+3.94%)
As of 04/2/2025

About Cortexyme Stock (NASDAQ:CRTX)

Key Stats

Today's Range
$1.26
$1.35
50-Day Range
$1.27
$1.72
52-Week Range
$1.78
$40.66
Volume
38,362 shs
Average Volume
620,672 shs
Market Capitalization
$39.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Remove Ads
Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

Crism Thera Regulatory News
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Headlines

CRTX Stock Analysis - Frequently Asked Questions

Cortexyme's stock was trading at $1.85 at the start of the year. Since then, CRTX shares have decreased by 28.6% and is now trading at $1.32.
View the best growth stocks for 2025 here
.

Cortexyme, Inc. (NASDAQ:CRTX) posted its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.05.

Cortexyme (CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

Last Earnings
8/09/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:CRTX
Fax
N/A
Employees
55
Year Founded
2012

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.33

Miscellaneous

Free Float
21,739,000
Market Cap
$39.80 million
Optionable
Not Optionable
Beta
1.40

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CRTX) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners